EZH2 and chronic myelogenous leukemia, BCR-ABL1 positive: Another interesting aspect of EZH2 as a therapeutic target is the potential application of specific inhibitors in well responding CML patients, where the primary goal is not to treat overt disease but to eliminate residual LSCs.